Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases

Launched by M.D. ANDERSON CANCER CENTER · Nov 14, 2018

Keywords

ClinConnect Summary

This clinical trial is looking at two different ways to use a treatment called stereotactic radiosurgery (SRS) for patients with brain metastases, which means cancer that has spread to the brain. The researchers want to find out if giving SRS before surgery is more effective than giving it after surgery. SRS uses focused, high-dose radiation to target tumors while minimizing the impact on the surrounding healthy brain tissue.

To participate in this trial, you should be between the ages of 65 and 74 and have a specific type of brain tumor that is not larger than a certain size. You also need to be in good health overall and agree to be randomly assigned to one of the treatment groups. If you join the trial, you will receive either the pre-operative or post-operative SRS treatment, and the doctors will closely monitor your health throughout the study. It's important to note that certain conditions, like previous radiation treatment to the brain or specific types of cancer, may exclude you from participating.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The primary lesion pre-operatively can have a maximum diameter of =\< 4 cm for single fraction and =\< 7 cm for multifraction therapy
• • Patients must be considered candidates for SRS within +/- 30 days of surgical resection as defined by either history and physical (H\&P) or presentation at brain metastasis tumor board conference note
• • Patients must have a Karnofsky performance scores \>= 70 or Eastern Cooperative Oncology Group (ECOG) \>= 2 within 30 days of enrollment
• • Patients must agree to randomization as documented by signing the Institutional Review Board (IRB) approved consent form
• • No radiographic evidence of leptomeningeal disease on MD Anderson Cancer Center (MDACC) departmental radiology report or study neuro-radiologist review
• • Documented history of malignancy
• Exclusion Criteria:
• • Patients who have received prior radiation therapy to the brain for any reason
• • The primary tumor is small-cell lung cancer, lymphoma, leukemia, or multiple myeloma
• • For females, if they are pregnant or breast-feeding (The exclusion is made because gadolinium may be teratogenic in pregnancy)